Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov;87:26-36.
doi: 10.1016/j.cyto.2016.06.017. Epub 2016 Jun 24.

JAK-STAT Signaling in Cancer: From Cytokines to Non-Coding Genome

Affiliations
Free PMC article
Review

JAK-STAT Signaling in Cancer: From Cytokines to Non-Coding Genome

Jan Pencik et al. Cytokine. .
Free PMC article

Abstract

In the past decades, studies of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) signaling have uncovered highly conserved programs linking cytokine signaling to the regulation of essential cellular mechanisms such as proliferation, invasion, survival, inflammation and immunity. Inhibitors of the JAK/STAT pathway are used for treatment of autoimmune diseases, such as rheumatoid arthritis or psoriasis. Aberrant JAK/STAT signaling has been identified to contribute to cancer progression and metastatic development. Targeting of JAK/STAT pathway is currently one of the most promising therapeutic strategies in prostate cancer (PCa), hematopoietic malignancies and sarcomas. Notably, newly identified regulators of JAK/STAT signaling, the non-coding RNAs transcripts and their role as important targets and potential clinical biomarkers are highlighted in this review. In addition to the established role of the JAK/STAT signaling pathway in traditional cytokine signaling the non-coding RNAs add yet another layer of hidden regulation and function. Understanding the crosstalk of non-coding RNA with JAK/STAT signaling in cancer is of critical importance and may result in better patient stratification not only in terms of prognosis but also in the context of therapy.

Keywords: Hematopoietic malignancies; JAK/STAT signaling; Non-coding RNAs; Prostate cancer; Sarcomas.

Conflict of interest statement

Potential competing interests

The authors have no conflict of interest and nothing to disclose.

Figures

Fig. 1
Fig. 1
Genetic alterations of STAT3 in solid malignancies. The structure of STAT3 is shown schematically, and the positions of STAT3 somatic mutations identified in primary tumor tissue of patients with solid malignancies are indicated.
Fig. 2
Fig. 2
Genetic alterations of STAT3 in hematopoietic malignancies. The structure of STAT3 is shown schematically, and the positions of STAT3 somatic mutations identified in patients with hematopoietic malignancies are indicated.
Fig. 3
Fig. 3
Integration of non-coding RNAs in regulation of canonical JAK/STAT network. Non-coding RNAs has to be considered in guiding of classical The JAK–STAT pathway. Direct regulation of JAK/STAT signaling by microRNAs, lncRNAs, and RNA-binding proteins promote various oncogenic and tumor suppressor processes and regulate transcription of STAT target genes. Negative regulators of JAK/STAT signaling are displayed in red, non-coding RNAs that promote signaling are displayed in green.

Similar articles

See all similar articles

Cited by 30 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback